| 1.JCI insight Single-cell profiling reveals GPCR heterogeneity and functional patterning during neuroinflammation. "12-4031 was used in Flow cytometry/Cell sorting to identify functionally distinct adaptive GPCR heterogeneity patternation in mice." Authors Tischner D,Grimm M,Kaur H,Staudenraus D,Carvalho J,Looso M,Günther S,Wanke F,Moos S,Siller N,Breuer J,Schwab N,Zipp F,Waisman A,Kurschus FC,Offermanns S,Wettschureck N 2.Journal of hematology and oncology Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia. "12-4031 was used in Flow cytometry/Cell sorting to evaluate the possible therapeutic role of anti-CXCR4 antibody PF-06747143 for chronic lymphocytic leukaemia in murine xenograft tumor model." AuthorsKashyap MK,Amaya-Chanaga CI,Kumar D,Simmons B,Huser N,Gu Y,Hallin M,Lindquist K,Yafawi R,Choi MY,Amine AA,Rassenti LZ,Zhang C,Liu SH,Smeal T,Fantin VR,Kipps TJ,Pernasetti F,Castro JE 3.PloS one Dermal γδ T Cells Do Not Freely Re-Circulate Out of Skin and Produce IL-17 to Promote Neutrophil Infiltration during Primary Contact Hypersensitivity. "12403182 was used in flow cytometry to test if dermal gammadelta cells freely re-circulate out of skin, or behave like dermal resident memory T cells in mice" AuthorsJiang X,Park CO,Geddes Sweeney J,Yoo MJ,Gaide O,Kupper TS 4.Molecular medicine reports Activation of the cholinergic anti-inflammatory system by nicotine attenuates arthritis via suppression of macrophage migration. "12-4031 was used in Flow cytometry/Cell sorting to indicate that nicotine-induced activation of the cholinergic anti-inflammatory pathway in mice with collagen-induced arthritis may aid in alleviating arthritis." AuthorsLi S,Zhou B,Liu B,Zhou Y,Zhang H,Li T,Zuo X 5.Molecular therapy oncolytics Intratumoral INF-γ triggers an antiviral state in GL261 tumor cells: a major hurdle to overcome for oncolytic vaccinia virus therapy of cancer. "12-4031 was used in Flow cytometry/Cell sorting to identify microenvironmental factors, which may be decisive for failure or success of oncolytic VACV therapy." AuthorsKober C,Weibel S,Rohn S,Kirscher L,Szalay AA | 
QQ:1749072012